Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Multiple REMS Programs May Create Risks For Pharmacists

Executive Summary

Pharmacists would of course like to get reimbursed for assisting with the administration of the Risk Evaluation and Mitigation Strategies for the products they dispense. But beyond that, they would like to see REMS standardized so that they can be used efficiently

You may also be interested in...



APhA Sells Location, Location, Location In Health Care Reform Debate

After President Obama's address to Congress, the focal point of the health care reform debate seems to be shifting to the Senate Finance Committee's pending markup of its legislation, but the American Pharmacists Association is continuing to focus on its pre-recess achievements

APhA Sells Location, Location, Location In Health Care Reform Debate

After President Obama's address to Congress, the focal point of the health care reform debate seems to be shifting to the Senate Finance Committee's pending markup of its legislation, but the American Pharmacists Association is continuing to focus on its pre-recess achievements

REMS For Opioids Still Has A Long Road Ahead; Advisory Committee Is Likely

A finalized Risk Evaluation and Mitigation Strategy for opioids is a long way off - possibly more than a year - and FDA expects additional stakeholder and industry meetings, as well as a multidisciplinary advisory committee to take place before a program is set in stone

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS051455

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel